Overview

A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Status:
RECRUITING

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.

Phase:

PHASE1

Details

Lead Sponsor:

GigaGen, Inc.

Collaborator:

National Cancer Institute (NCI)